Overview

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

Status:
Completed
Trial end date:
2021-04-28
Target enrollment:
Participant gender:
Summary
This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a conventional synthetic disease modifying anti-rheumatic drug. This is a China alone study.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Tofacitinib